Evidence map›Paper›PMID 35665122›Full record

ReviewWorld journal of clinical cases2022

COVID-19 and liver diseases, what we know so far.

Mohamed Elnaggar, Ahmed Abomhya, Ismail Elkhattib, Nabila Dawoud, Rajkumar Doshi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Effect of SARS-CoV-2 infection on the liver.World journal of virology · 2023
    Review
  5. COVID-19 and liver injury: An ongoing challenge.World journal of gastroenterology · 2023
    Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohamed ElnaggarDepartment of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV 89052, United States. mohamed.elnaggar.md@gmail.com.
Ahmed AbomhyaDepartment of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY 11200, United States.
Ismail ElkhattibDepartment of Internal Medicine, University of Connecticut, Farmington, CT 06030, United States.
Nabila DawoudDepartment of Internal Medicine, University of Kentucky, Lexington, KY 40508, United States.
Rajkumar DoshiDepartment of Cardiology, St Joseph's University Medical Center, Paterson, NJ 07503, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) pneumonia outbreak started in December 2019. On March 12, 2020, the World Health Organization (WHO) declared that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a pandemic, and as of May 2021, SARS-CoV-2 has infected over 167.3 million patients, including 3.4 million deaths, reported to WHO. In this review, we will focus on the relationship between SARS-CoV-2 infection and the liver. We will discuss how chronic liver diseases affect the COVID-19 disease course and outcomes. We will also discuss the SARS-CoV-2 effects on the liver, mechanisms of acute liver injury, and potential management plans.

Indexed as

COIVD-19Hepatocellular carcinomaLiver diseasesNon alcoholic fatty liverSARS-CoV-2Transaminases

Identifiers

PMID35665122
PMCPMC9131221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.